Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celon PharmaLTS:0RKX 19 EV-to-EBITDA is 4.46 as of Aug. 15, 2026, which is 87% below its 10-year median of 33.74. GuruFocus rates LTS:0RKX with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 735 Drug Manufacturers companies, Celon Pharma ranks better than 88.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Celon Pharma's enterprise value is zł859.3 Mil.
Celon Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was zł192.8 Mil. Therefore, Celon Pharma's EV-to-EBITDA for today is 4.46.
The historical rank and industry rank for Celon Pharma's EV-to-EBITDA or its related term are showing as below:
LTS:0RKX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -276.21 Med: 33.74 Max: 342.01
Current: 4.43
During the past 11 years, the highest EV-to-EBITDA of Celon Pharma was 342.01. The lowest was -276.21. And the median was 33.74.
LTS:0RKX's EV-to-EBITDA is ranked better than 88.3% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.3
vs LTS:0RKX: 4.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Celon Pharma's PE Ratio (TTM) for today is calculated as:
Celon Pharma's share price for today is zł22.50.
Celon Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Celon Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKX vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Celon Pharma's EV-to-EBITDA falls into.
Celon Pharma's current Enterprise Value is zł859.3 Mil.
Celon Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł192.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (LTS:0RKX) has a EV-to-EBITDA of 4.46 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Celon Pharma. This is 87% below median its historical median of 33.74. According to the industry distribution chart, Celon Pharma ranks #86 out of 735 companies in the Drug Manufacturers industry, placing it in the top 11.7%.
Is Celon Pharma's EV-to-EBITDA too high?
Celon Pharma's current EV-to-EBITDA of 4.46 is 87% below median its 10-year median of 33.74. The Drug Manufacturers industry median EV-to-EBITDA is 13.30. Celon Pharma's value of 4.46 is 66.5% below this industry median. Based on the distribution chart, Celon Pharma ranks #86 out of 735 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #86 out of 735 companies for EV-to-EBITDA. This places Celon Pharma in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.30. Celon Pharma's value of 4.46 is 66.5% below this benchmark. While the company's 10-year median is 33.74 vs. the industry median of 13.30, Celon Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.30, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current EV-to-EBITDA of 4.46 is 66.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Celon Pharma. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current EV-to-EBITDA is 4.46, which is 87% below median its own 10-year median of 33.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current EV-to-EBITDA of 4.46. The current EV-to-EBITDA is 4.46, which is 87% below median its 10-year median of 33.74 and 66.5% below the Drug Manufacturers industry median of 13.30. Celon Pharma's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current EV-to-EBITDA is 4.46 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
19GF Score
Get the complete analysis for LTS:0RKX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKX has been successfully added to your 
